Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study

We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29·8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49·3% (75/1...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchesini, Gessica, Nadali, Gianpaolo, Facchinelli, Davide, Candoni, Anna, Cattaneo, Chiara, Laurenti, Luca, Fanci, Rosa, Farina, Francesca, Lessi, Federica, Visentin, Andrea, Marchesi, Francesco, Prezioso, Lucia, Spolzino, Angelica, Tisi, Maria Chiara, Trastulli, Fabio, Picardi, Marika, Verga, Luisa, Dargenio, Michelina, Busca, Alessandro, Pagano, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy – Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246914/
https://www.ncbi.nlm.nih.gov/pubmed/33058237
http://dx.doi.org/10.1111/bjh.17145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246914/
https://www.ncbi.nlm.nih.gov/pubmed/33058237
http://dx.doi.org/10.1111/bjh.17145

Ejemplares similares